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Abstract: 
Different classes of compounds were investigated for their binding affinities into different protein tyrosine kinases (PTKs) employing a novel flexible 
ligand docking approach by using AutoDock 3.05 and 4. These compounds include many flavin analogs, which were developed in our group with varying 
degrees of cytotoxic activity (comparable or moderately superior to cisplatin and ara-c), and database selected analogs. They were docked onto twelve 
different families of PTKs retrieved from the Protein Data Bank. These proteins are representatives of plausible models of interactions with   
chemotherapeutic agents.  A comparative study of the intact co-crystallized ligands of various types of PTKs was carried out. Results revealed that the 
new class of 5-deazapteridine and steroid hybrid compounds VIa,b, and d, and the vertical-type bispyridodipyrimidine with n-hexyl chain junction 
between its N-10 and N-10 atoms Xa, exhibited non-selective PTK binding capacities, with the lowest ￿Gb. On the other hand, 2-amino benzoic acid 
analog IIa, phenoxypyrido [3, 4-d]pyrimidine derivative IVc, tyrosine containing tripeptide Vd, and the one from Sumisho data base 831 are proposed to 
have selective PTK binding affinities to certain classes of tyrosine kinases, namely, HGFR (c-met), ZAP-70, insulin receptor kinase, EGFR, respectively. 
All These compounds of highest affinities were docked within the binding sites of PTKs with reasonable RMSD and 1-5 hydrogen bonds.  
 
 
 
 
 
Background: 
In 2009, two kinase inhibitors were approved for the treatment of cancer; 
and another for the treatment of renal cell carcinoma [1]. Protein-tyrosine 
kinases (PTKs) play an important role in the control of most fundamental 
cellular processes including the cell cycle, cell migration, cell metabolism, 
and cell survival, as well as cell proliferation and differentiation [2].  
Docking of the molecules into their respective 3D macromolecular targets 
is a widely used method for lead optimization [3]. Docking programs find 
their most important applications in virtual database screening approaches 
in which hundreds of thousands of molecules are docked into the binding 
pocket to identify plausible binders [4]. It was reported that docking 
programs are able to predict experimental poses with deviation average 
from 1.5 to 2.0 Å root mean square deviation (RMSD) [5]. One of the most 
well-known docking programs is Autodock [6].   Structure-based drug 
design methods utilize knowledge of the three-dimensional structure of a 
receptor complexed with a lead molecule in an attempt to optimize the 
bound ligand or a series of congeneric molecules. Using a model with a 
given structure, a medicinal chemist can compute an activity of a molecule 
[7]. 
 
Development of PTK signaling inhibitors has evolved into an important 
approach toward new therapeutics [8]. Tyrosine kinase inhibitors as a 
target for anti-angiogenesis can be aptly applied as a new mode of cancer 
therapy [9]. The role of tyrosine kinases in cancer molecular pathogenesis 
is immense and recently tyrosine kinases have come in vogue as potential 
anticancer drug targets, sending a number of anticancer drugs to the 
market. Several tyrosine kinase inhibitors are undergoing human trials and 
several are in the pipeline of drug discovery [10]. 
 
The main objective of this study is to design and to propose potential 
tyrosine kinase inhibitors from synthesized compounds and database-
selected analogs. In this study twelve different target protein tyrosine 
kinases were selected to investigate the potential binding affinities within 
their corresponding binding sites. Those include fibroblast growth factor 
receptor, epidermal growth factor receptor, hepatocyte growth factor 
receptor, insulin receptor kinase, sarcoma proto-oncogenic kinase, spleen 
tyrosine kinase, platelet-derived growth factor receptor, vascular 
endothelial growth factor receptor, Abelson tyrosine kinase, hemopoietic 
cell kinase, Zeta-chain-associated protein kinase, and Janus kinase.  
 
The selective PKC inhibitory activities of 5-deazaflavins, 2-deoxy-2-
phenyl-5-deazaflavins, {2-phenylpyrimido[4, 5-b]quinolin-4(10H)-ones}, 
and their effective growth inhibition against cancer cells such as the A431 
cells, and HT1080 cells were reported [11]. Synthesis of the hybrid 
compounds, which structurally contain two different biologically or 
pharmacologically active compounds of 5-deazaflavins and steroids in the 
same ring system, were carried out by condensation of 6-(monosubstituted 
amino)uracils or 6-(monosubstituted amino)-2-phenylpyrimidin-4(3H)-
ones with 2-hydroxy-methylene androstanolone or 2-
hydroxymethylenetestosterone.  Eventually, their potential anti-coccidiosis 
activities were reported [12]. These compounds were synthesized with the 
rationale that steroids can penetrate the cell membrane, and bind the cell 
nucleus.  Steroid receptors may serve to localize and concentrate appended 
drug species, mainly in hormones responsive for the production of 
neoplastic cells. Moreover, 5-deazaflavins (5-deazaisoalloxazines) have 
greatly attracted our attention [13–17]. Antitumor activities of nitro-5-
deazaflavin-pyrrolecarboxamide hybrid molecules [18] and 5-amino-5-Bioinformation  Volume 5  open access 
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deazaflavin derivatives revealed potential inhibitory activities against 
L1210 or KB cells [19]. 
 
Methodology:               
AutoDock protocol:   
Firstly, all bound waters, ligands and cofactors were removed from the 
proteins. The macromolecule was checked for polar hydrogens, partial 
atomic Kollman charges were assigned, and then atomic solvation 
parameters were allotted.  Torsion bonds of the inhibitors were selected 
and defined. Secondly, the three dimensional grid box was created by 
AutoGrid algorithm to evaluate the binding energies on the macromolecule 
coordinates. The grid maps representing the intact ligand in the actual 
docking target site were calculated with AutoGrid (part of the AutoDock 
package). The three dimensional grid box with 60 Å grid size (x, y, z)  with 
a spacing of 0.300 Å, grid was created.  Eventually cubic grids 
encompassed the binding site where the intact ligand was embedded. 
Finally, AutoDock was used to calculate the binding free energy of a given 
inhibitor conformation in the macromolecular structure while the probable 
structure inaccuracies were ignored in the calculations.  
 
Target macromolecules investigated:  
Twelve different target protein tyrosine kinases were investigated, and 
those were retrieved from the Protein Data Bank, 
http://www.rcsb.org/pdb/home/home.do.  For each docking  target, crucial 
amino acids of the active site were identified using data in PDBsum, 
http://www.ebi.ac.uk/pdbsum/.  
 
Compounds involved in this study:  
The compounds investigated in this study   include 2, 3, 4-trisubstitutred-
1, 2-dihydropyrrolo[1, 2-a][1, 3, 5]triazin derivatives Ia-k, 4-(3, 5-di-tert-
butylphenylcarbamoyl)-2-amino benzoic acid, or 2-nitro benzoic acid, or 
their methylester analogs IIa-d, benzopyrido, benzopyrimido, or 
benzopiprazino[1, 4]dioxin-2-ol IIIa-c and dipyrido[1, 4] dioxin-2-ol 
analogs IIId-g, 2-substituted-(6-fluoro-3, 4-dihydro-4-substituted pheno-
xypyrido[3, 4-d]pyrimidin-2-yl) derivatives IVa-d, tyrosine containing di- 
or tripeptides Va-f, acetylated tyrosine containing tetrapeptides analogs 
Vg-m, deazapteridine-steroid hybrid compounds VIa-d, as a new class of 
the hybrid compounds possessing 5-deazapteridine and steroid in the same 
ring system, synthesized by condensation of 6-(monosubstituted amino) 
uracils or 6-(monosubstituted amino)-2-phenylpyrimidin-4(3H)-ones with 
2-hydroxy-methylene androstanolone or 2-hydroxymethyl- enetestosterone 
under heating in the presence of p-toluenesulfonic acid monohydrate.12 5-
deazaflavin derivatives including: 2-deoxo-2-phenyl-5-deazaflavins VIIa-
h,13,142-deoxo-2-piperidino-5-deazaflavin VIIi,15 2-deoxo-2-morpholino-
5-deazaflavin VIIj,15 new 2-deoxo-2-phenylflavins VIIm-o, 
computationally newly designed 2-deoxo-2-glycino, 2-tyrosino, and 2-
histidi- no-N10-methylflavin-N-oxides VIIp-r, respectively, new 5-
deazaflavin derivatives VIIIa-c, N3-methyl -5-(monosubstituted 
alkylamino)-5-deazaflavin derivatives VIIId-g, and 14 computationally 
designed pyridodipyrimidines  IXa-f, 14 bis-(5-deazaflavin-10-yl) alkanes 
Xa,14 and Xb. Additional compounds were obtained from  Sumisho data 
base  (Figure 1). Those include abacavir, PB-01547328, PB-99211665, 
F0007-0958, OSSK-633719, OSSK-692604, 831, PB-00623451, and 
compound 1505335. 
       
Analysis of the docking results:  
Accelrys DS modeling 1.7 software [DS modeling 1.7; Accelrys Inc., San 
Diego, CA, (2006), www.accelrys.com], and Accelrys DS Visualizer 2.5 
were utilized for molecular modeling, for evaluation of hydrogen bonds in 
ligand–receptor interaction, and for measuring RMSD which was 
computed and expressed in angstrom (Å) as a locational comparison of two 
molecules of interest. In our particular study RMSD was measured as 
distance between the centroids of the docked inhibitor and the intact 
ligand.  
 
Results and Discussion: 
We investigated the AutoDock binding affinities of various structures for 
their potential protein tyrosine inhibitory activities, including: 2, 3, 4-
trisubstitutred -1, 2-dihydropyrrolo[1, 2-a][1, 3, 5]triazin derivatives Ia-k, 
4-(3, 5-di-tert-butylphenylcarbamoyl)-2-amino benzoic acid, its 2-nitro 
benzoic acid, their methylester analogs IIa-d such as benzopyrido, 
benzopyrimido, benzopiprazino [1,4] dioxin-2-ol IIIa-c,  dipyrido[1, 4] 
dioxin-2-ol analogs IIId-g, 2-substituted-(6-fluoro-3,4-dihydro-4-
substituted pheno-xypyrido [3, 4-d] pyrimidin-2-yl) derivatives IVa-d, 
tyrosine containing di- or tripeptides Va-f, acetylated tyrosine containing 
tetrapeptides analogs Vg-m, deazapteridine-steroid hybrid compounds VIa-
d, hybrid compounds possessing 5-deazapteridine and steroid in the same 
ring system [12],  2-deoxo-2-phenyl-5-deazaflavins VIIa-h [13, 14],  2-
deoxo-2-piperidino-5-deazaflavin VIIi [15], 2-deoxo-2-morpholino-5-
deazaflavin VIIj [15],  2-deoxo-2-phenylflavins VIIm-o, computationally 
newly designed 2-deoxo-2-glycino, 2-tyrosino, 2-histidino-N10-
methylflavin-N-oxides VIIp-r, 5-deazaflavin derivatives VIIIa-c, N3-
methyl-5-(monosubstituted alkylamino)-5-deazaflavin derivatives VIIId-g 
[14], computationally designed pyridodipyrimidines  IXa-f [14],  and bis-
(5-deazaflavin-10-yl) alkanes Xa,b  [14].  Additional structures obtained 
from Sumisho Data Base were studied, including abacavir, PB-01547328, 
PB-99211665, F0007-0958, OSSK-633719, OSSK-692604, 831, PB-
00623451, and compound 1505335. 
 
Molecular docking study: 
Computer simulated automated docking studies were performed using the 
widely distributed molecular docking software, AutoDock versions  3.05 
and 4.0,  grid-based docking programs [6], which was utilized for the study 
of binding mode of the suggested potential inhibitors within different 
tyrosine kinases.  In AutoDock, the overall  docking energy of a given 
ligand molecule is expressed as the sum of intermolecular interaction 
energies including van der Waals attractive  and repulsive energies, H-
bond interaction energy, coulombic electrostatic energy, and the internal 
steric energy of the ligand [4]: 
 
Evaluation of docking performance and accuracy:  
As shown in Table 1 (see Supplementary material), the RMSD values 
for the representative examples range from 0.07-1 Å to 16 Å. It was found 
that the docked ligands are exactly superimposed with the originally 
embedded intact ligands not only for the best-scored conformations, but 
also for all the docked conformations. The docked compound (PRC1), 1-
terbutyl-3-p-tolyl-1h-pyrazolo[3, 4-d]pyrimidin-4-ylamine ligand,   
exhibited the best RMSD of 0.07Å, and a low binding free energy (￿Gb)  
of -11.56 Kcal/mol. The representative examples of PTKs exhibited fairly 
reasonable docking results well comparable to their originally embedded 
intact ligands.  Hence the obtained docking results were well correlated 
with the biological methods [20]. 
 
AutoDock binding affinities of the synthesized and designed 
compounds into PTKs –overview: 
The molecular docking study revealed that many of the docked compounds 
currently studied exhibited the fairly good docking results into different 
PTKs in comparison with their originally embedded intact co-crystalized 
ligands. These promising compounds as drugs include: 4-(3, 5-di-tert-
butylphenylcarbamoyl)-2-amino benzoic acid IIa, 4-(3, 5-di-tert-
butylphenylcarbamoyl)-2-nitro benzoic acid IIb, 2-(1-piprazin-ylethyl)-6-
fluoro-3, 4-dihydro-4-(3, 4-dihydroxy) phenoxypyrido [3, 4-d]pyrimidine 
IVc, tyrosine containing tripeptide; Trp-Glu-Tyr-OH Vd, 3'and/or8'-
disubstituted-5'-deaza-androsta[2, 3-g]pteridine-2', 4'(3'H,8'H)-diones 
VIa,b, and d, 5-deazaflavin derivatives including: 2-deoxo-2-phenyl-10-
methyl-5-deazaflavin-7-carboxylic acid VIIa, 2-deoxo-2-piperidino-7,10-
dimethyl-5-deazaflavin VIIi, 2-deoxo-2-tyrosino-5-deazaflavin VIIl, 
designed 2-deoxo-2-tyrosino, and 2-histidino-N10-methylflavin-N-oxides 
VIIq,r, N3-phenyl-8-chloro-N10-(3,4-xylyl)-5-deazaflavin VIIIb, N10-
dodecyl-5-deazaflavin VIIIc,  N3-methyl-5-phenethyl-N10-n-octyl or n-
dodecyl-5-deazaflavin derivatives VIIIf,g, designed 2, 3, 8, 10-tetraphenyl-
pyridodipyrimidines  IXc, vertical bis-(5-deazaflavin-10-yl)-n-hexane Xa, 
and   structure database coded 831.              
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Figure 1: Structures of the compounds tested for the tyrosine kinase inhibition by computer docking 
 
Docking evaluation for FGFR inhibitors:        
The designed compound VIIq, 2-deoxo-2-tyrosino-N10-methylflavin-N-
oxides, was docked against FGFR (pdb code: 1agw) occupying  the site in 
which the adenine of adenosine triphosphate binds, and the  binding free 
energy (￿Gb) was -11.85 kcal/mol, with  RMSD of 5.44Å, where it was 
slightly deviated from the originally embedded intact ligand, indolinone 
(SU4984).   
 
Docking evaluation for EGFRK inhibitors:                                                                                                                                      
Compound IVc, 2-(1-piprazinylethyl)-6-fluoro-3, 4-dihydro-4-(3, 4-
dihydroxy) phenoxy pyrido[3, 4-d]pyrimidine, was bound into EGFRK 
(pdb code: 1m17) and exactly superimposed on erlotinib (TarcevaTM) 
currently marketed for the treatment of non-small cell lung cancer. The 
binding free energy (￿Gb) was reasonably as small as -10.77 kcal/mol, 
and five hydrogen bonds were formed via its polar 3, 4-dihydroxy and 2-
pirazinyl N-H groups.  
 
Docking evaluation for SRC inhibitors: 
The nonreceptor tyrosine kinase SRC (Pp60v-src; pdb code: 1skj) which, is 
considered to be causative protein for breast cancer and osteoporosis, was 
investigated by docking of the hybrid steroidal molecule, 8'-methyl-5'- 
deaza-androsta [2, 3-g]pteridine-2', 4'(3'H,8'H)-diones VIa. The docked 
compound VIa  penetrated  to the intracellular Src SH2 domain target, 
exerting four hydrogen bonds between the pair of its 2-oxo, N3H, and 
17OH, and amino acids of binding site, namely Arg62, Ile71, and Arg32, 
respectively as shown in Table 1(see Supplementary material).  
 
Docking evaluation for Syk inhibitors: 
The docked compound VIIb,  3', 8'-dimethyl-5'-deaza-androsta[2, 3-
g]pteridine-2', 4'(3'H, 8'H)-diones, was bound deeply into non-receptor 
spleen tyrosine kinase (SYK; pdb code:1xbb) into the activation loop 
typically to the intact ligand, Gleevec (STI-1, Imatinib) within 2.24Å 
RMSD. The binding free energy was -11.58 kcal/mol, involving three 
hydrogen bonds via its polar moieties, 2-oxo and 17-OH  groups. 
Docking evaluation for HGFR inhibitors: 
2-deoxo-2-phenyl-10-methyl-5-deazaflavin-7-carboxylic acid VIIa was 
shown to be potentially bound deeply within hepatocyte growth factor 
receptor (HGFR/c-Met; pdb code: 1r0p); with low binding free energy 
(ΔGb)  being -11.13 kcal/mol, and with low inhibition constant (Ki) being 
6.98E-09. It exhibited two hydrogen bonds between the pair of its 7-
COOH, 7-C=O and O of Asp1231 and HN of Lys1232, with their   
distances being 1.88Å, and 1.99Å, respectively,  while its RMSD was 
3.11Å from the intact ligand, K-252a. Vertical bis-(N3-methyl-5-
deazaflavin-10-yl)-n-hexane Xa, was unselectively bound into HGFR/c-
Met (pdb code: 1r0p), which is considered to be an  important cancer drug 
target, as there is a strong link between aberrant c-Met activity and 
oncogenesis [20].        
 
Docking evaluation for ABL inhibitors: 
The activation of ABL tyrosine kinanse causes chronic myelogenous 
leukemia (CML). Therefore, inhibitors of this PTK is proposed to be 
effective in the treatment of CML. Thus herein compound VIIIb, N3-
phenyl-8-chloro-N10-(3, 4-xylyl)-5-deazaflavin, was tested for docking   
into Abelson tyrosine kinase (ABL, pdb code: 1fpu) to find  potential 
inhibitor candidate. Compound VIIIb exerted binding free energy (￿Gb) of 
-11.09 kcal/mol, with RMSD of 4.49Å, and one hydrogen bond between its 
2-oxo group and OH of Thr315 was formed.       
 
Docking evaluation for PDFGR inhibitors: 
The activity of the c-Kit receptor protein-tyrosine kinase is tightly 
regulated in normal cells, whereas the deregulated c-Kit kinase activity is 
implicated in the pathogenesis of human cancers Based on its finding, 
compound VIIl, 2-deoxo-2-tyrosino-5-deazaflavin, was studied for its 
potential binding into platelet-derived growth factor receptor (PDGFR,c-
kit, pdb code: 1t46) as shown in Table 1.   It was found that the docked 
compound VIIl was bound to Tyr670 identically to the intact ligand STI-
571 by two hydrogen bonds via 2-tyrosinyl COOH group, exerting binding 
free energy (ΔGb) of within -11.32 kcal/mol.  Bioinformation  Volume 5  open access 
www.bioinformation.net  Issue 9   Hypothesis
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Docking evaluation for VEGFR inhibitors: 
Compound VIIIf, N3-methyl-5-phenethyl-N10-n-octyl-5-deazaflavin, was 
docked into vascular endothelial growth factor receptor (VEGFR-2; pdb 
code: 1y6a) and showed two hydrogen bonds via its 4-oxo group with HN 
of Asn 921.  It exhibited the best RMSD among this series of compounds.  
                                                                            
Docking evaluation for ZAP-70 inhibitors: 
The ZAP-70 tyrosine kinase plays a critical role in T cell activation as well 
as in the immune response, and thus it has become a logical target for 
immunomodulatory therapies. Based on this background, against ZAP-70 
tyrosine kinase (pdb code: 1u59) compound IIb, 4-(3, 5-di-tert-
butylphenylcarbamoyl)-2-nitro benzoic acid, was docked within the 
binding site resulting in a strong binding affinity.     
 
 Docking evaluation for insulin receptor kinase inhibitors: 
Tyrosine containing tripeptide, Trp-Glu-Tyr-OH Vd  is structurally similar 
to the structure  of the intact ligand of the insulin receptor kinase (pdb 
code: 1rqq),  thiophosphoric acid o-(adenosyl-phospho)phospho)-s-
acetamidyl-diester  (112 E), where there is a ring equivalence between the 
indole and adenine rings of both compounds.  In addition, the structural 
similarity exists between of tripeptides of Vd and triphosphate moiety of 
112E. The docked compound Vd was exactly  superimposed on and 
identically to the intact ligand within 1.32Å RMSD exhibiting five 
hydrogen bonds between  the pair of  its COOH groups, indolyl-NH, and 
phenoxy-p-OH and amino acids of the binding sites, Gln1004, Lys1030, 
Met1079, and Ser1006, respectively, as shown in Table 1(see 
Supplementary material).  
 
Docking evaluation for HCK inhibitors: 
The docked compound VIIIg, was shown to be superimposed with the 
intact ligand PP1-532 of non-receptor tyrosine kinase, (HCK; pdb code: 
1qcf)   and was bound at the ATP-binding site of the kinase, exhibiting one 
hydrogen bond with lys295.  Its lipophilic n-dodecyl moiety comparable to 
the p-tolyl moiety of intact ligand PP1-532 was inserted into an adjacent 
hydrophobic pocket created by VaL281, Lys295, Ile336, and Asp404.    
 
Docking evaluation for JAK3 inhibitors: 
Compound VId, 5-deazapteridine and steroid hybrid compound, namely,   
3'-methyl, 8'-phenyl-5'-deaza-androsta[2, 3-g]pteridine-2', 4'(3'H, 8'H)-
diones,  was bound firmly against non-receptor tyrosine kinase, Janus 
kinase (JAK3; pdb code: 1yvj). Janus kinase is a central mediator of 
cytokine signaling. This provides a detailed view of the Jak3 active site, 
where VId exhibits one hydrogen bond between its 17-OH group and O of 
gly831 within RMSD of 2.10Å. 
 
Docking evaluation for tested PTK inhibitors in general: 
To summarize all the aforementioned docking results, it was found that 19 
compounds out of 85 exhibited noteworthy docking results. Those 
compounds include 4-substituted-2-amino and 2-nitro benzoic acid analogs 
IIa,b, 2, 4, 6-substituted phenoxypyrido[3, 4-d]pyrimidine IVc, tyrosine 
containing tripeptide Vd, 5-deazaandrosta [2, 3-g]pteridine derivatives VIa, 
b, d, 5-deazaflavin and flavin-N-oxide derivatives VIIa, i, l, q, r, N3-
phenyl-8-chloro-N10-(3, 4-xylyl)-5-deazaflavin VIIIb, N10-dodecyl-5-
deazaflavin VIIIc, 5-phenethyl-N10-n-octyl or n-dodecyl-5-deazaflavins 
VIIIf, g,  pyridodipyrimidine derivative IXc, bis-(5-deazaflavin-10-yl)-n-
hexane Xa,  and Shumisho database compound 831.   
 
Conclusion: 
3'and/or8'-disubstituted-5'-deaza-androsta[2, 3- g] pteridine-2', 4'(3'H, 
8'H)-diones VIa, b, and d, vertical bis-(5-deazaflavin-10-yl)-n-hexane Xa, 
exhibited remarkable non-selective PTK binding affinities. They presented 
the lowest ΔGb on docking against different classes of PTKs, i.e. -9.46~                         
-13. 28, and -0.20 – -13.74 kcal/mol.  Hydrogen bonds were formed from 
ranging from one to four and zero to three with the distance of 1.60 ~ 4.49 
Å, and 0.72 ~ 3.08 ￿, respectively. Both of 2-substituted 2-deoxo-5-
deazaflavin and flavins VIIa, i. l, q, r and 5-unsubstituted and 5-
substituted-5-deazaflavins VIIIb, c, f, g also exhibited nonselective fine 
docking results within different PTKs. Furthermore, compounds  IIa, IVc, 
Vd, and 831 demonstrated   to possess selective PTK binding affinities to 
certain classes of tyrosine kinases, namely: HGFR (c-met), ZAP-70, 
insulin receptor kinase, and EGFR, respectively. These findings revealed 
that hybrid compounds of 5-deazaflavins and steroids, that is, VIa, b, and 
VId would be promising candidates as antitumor agents.   
 
Replacement of pyrimidoquinoline ring of 5-deazaflavins or 
benzopteridine ring of flavins with pyridodipyrimidines (IXc) as a new 
NAD-type redox catalyst produced compounds with excellent docking 
binding affinities wherein 2,7,8,10-tetraphenyl substitution enabled planar 
interaction within the target site so as to produce  favorable docking 
affinity. Moreover, tyrosine containing tripeptide, Trp-Glu-Tyr-OH (Vd), 
was found to compose a  platform to produce small lead compounds as 
PTK inhibitors  which exhibit selective insulin receptor kinase binding 
affinity due to  its close structural  resemblance to the intact ligand of the 
insulin receptor kinase (pdb code: 1rqq). 
 
The amino acid coupled with 2-deoxo-5-deazaflavin and flavins (VII l, q, 
r) has been shown to enhance remarkably the binding affinities in PTK. 
The higher affinity of these designed derivatives is presumably attributed 
to the formation of more hydrogen bonds (2–4 hydrogen bonds) between 
their 2-amino acid moieties and the binding site residues.  
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Supplementary material: 
 
Table 1: AutoDock binding free energies (ΔGb), inhibition constants (Ki), RMSD values, and hydrogen bonds of the top three ranks of the docked 
inhibitors against different protein tyrosine kinases 
Hydrogen bonds between atoms of compounds and amino 
acids of PTK  PDB code  Top ranked 
inhibitors 
ΔGb 
(kcal/mol) 
Ki 
atom of comp.  amino acid  distance (Å) 
RMSD (Å) 
1)   VIIq  -11.85 
2.05E-09 
COOH 
2-NH 
p-OH 
O of Asp641 
O of Asp641 
O of Glu562 
1.05 
1.91 
1.26 
5.44 
2) VIa  -11.51  3.66E-09  4-Oxo 
17-OH 
HN of Lys514 
O of Glu571 
1.79 
2.33  4.42 
1agw 
3) VIb  -10.96  9.28E-09  2-Oxo  HN of Lys514  2.05  4.49 
1)   IVc 
-10.77  1.28E-08 
p-OH 
m-OH 
m-O 
piprazinyl-NH 
piprazinyl-NH 
O of Met769 
O of Gln 767 
HN of  Met769 
O of Thr766 
O of Ala719 
1.94 
2.32 
2.18 
2.48 
2.15 
3.54 
2)   VIb  -10.66  1.55E-08  2-Oxo 
17-OH 
HN of Gly697 
O of Glu738 
2.49 
2.25  3.73  1m17 
3) VIIr 
-10.52  1.95E-08 
histadinyl-CO 
histadinyl-COO 
imidazolyl-NH 
imidazolyl-NH 
HN of Asp831 
HN of Lys721 
O of Leu764 
O of Ala719 
 1.91 
 2.20 
 2.34 
 1.81 
2.68 
1)   Xa  -11.90  1.90E-09  4-Oxo  HN of Met1160  2.15  0.72 
2)   IIa 
-11.41  4.30E-09 
p-COOH 
m-NH 
m-NH 
O of Asp1231 
O of Asp1228 
O of Asp1228 
2.19 
2.11 
2.07 
1.88  1r0p 
3) 831  -9.23  1.73E-07  p-Cl  HN of  Lys1110  2.49  0.87 
1)   IVc 
-13.58  1.10E-10 
p-OH 
m-OH 
m-O 
piprazinyl-NH 
O of Thr1031 
N of Tyr1031 
HN of Tyr1031 
O of Asp1150 
1.99 
2.33 
2.43 
2.20 
4.86 
2)   VId  -13.48  1.37E-10  17-OH  OH of Ser 1006  2.06  1.74  1rqq  3) Vd 
-11.34  4.88E-09 
COOH 
CO 
COO 
indolyl-NH 
phenoxy p-O 
O of Gln1004 
HN of Lys1030 
HN of Lys1030 
O of Met1079 
HO of Ser1006 
2.28 
1.85 
2.13 
2.24 
2.44 
1.32 
1)   VIa 
-11.24  5.78E-09 
2-Oxo 
N3-H 
17-O 
17-O 
HN of Arg62 
O of Ile71 
HN of Arg32 
HN of Arg32 
2.13 
2.29 
2.19 
 1.65 
2.95 
2)   VIIa 
-9.71  7.65E-08 
4-Oxo 
7-CO 
7-CO 
7-CO 
HN of Lys60 
HN of Lys60 
HO of Thr36 
HO of Ser34 
1.87 
2.06 
2.33 
1.75 
2.35 
1skj 
3) VIIIb  -8.09  1.18E-06    ---a    1.79 
1)   VIb 
-11.39  4.47E-09 
2-Oxo 
17-OH 
17-OH 
HN of Ala451 
N of Gly380 
O of Gly383 
2.14 
2.24 
1.88 
2.24 
2)   VId  -10.79  1.24E-08  17-OH  O of Gly383  1.67  1.60  1xbb 
3) Xa 
-10.61  1.67E-08 
4-OxoTricycleA 
4-OxoTricycleA 
4-OxoTricycleB 
HN of Phe382 
HN of Asn381 
HN of Ala451 
2.31 
2.08 
1.79 
2.63 
1)   VIIi  -15.12  8.31E-12    ---a    4.22 
2)   Xa  -12.62  5.61E-10    ---a    1.42  1t46  3) VIIl  -11.32  5.07E-09  TyrosinylCOOH 
TyrosinylCOOH 
OH of Thr670 
N of Thr670 
2.26 
 2.31  4.29 
1)   Xa  -10.20  3.33E-08  4-OxoTricycleA 
4-OxoTricycleB 
HN of Lys866 
HN of Asn921 
2.10 
1.98  1.06 
2)   VIIIf  -9.75  7.18E-08  4-Oxo  
4-Oxo  
HN of Asn921 
HN of Asn921 
2.44 
2.36  1.02  1y6a 
3) VId  -9.46  1.16E-07  17-OH 
17-OH 
O of Glu915 
HN of Asn921 
1.78 
1.79  1.78 
1fpu 1)    Xa  -13.74  8.45E-11    ---a    3.08 Bioinformation  Volume 5  open access 
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2)   VIb  -11.44  4.13E-09  17-OH  O of Tyr253  2.34  3.94 
3) VIIIb  -11.09  7.40E-09  2-Oxo   HO of Thr315  1.77  4.49 
1)   VIIIg  -11.52  3.62E-09  2-Oxo   HN of Lys295   1.59  1.06 
2)   VIIIc  -11.31  5.11E-09  4-Oxo   HN of Met 341   1.72  3.99  1qcf  3) VIb  -11.09  7.44E-09  17-OH 
17-O 
O of Glu339 
HN of Met341 
 2.08 
 2.05  3.02 
1)   VIa  -11.10  7.33E-09  N3-H  O of Glu386   2.26  2.48 
2)   IIb  -10.52  1.93E-08  p-CO 
m-NO 
HN of His423 
HN of Lys424 
 2.17 
 1.70  1.99  1u59 
3) VIIr  -10.06  4.24E-08  4-Oxo  
5-N-O 
HN of Ala417 
HN of Ala417 
 1.93 
 2.90  1.63 
1)   VId  -12.48  7.13E-10  17-OH  O of Gly831  2.35  2.10 
2)   Xa  -12.36  8.76E-10  4-OxoTricycleA  HN of Lys855  2.31  1.03  1yvj 
3) VIIIf  -10.81  1.18E-08  4-Oxo  HN of Lys855   2.33  3.18 
1) to 3) represent  top ranked  three compounds based on their binding free energies.     
a represent that no hydrogen bond was detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 